
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is favored because IBSRELA continues to show strong underlying demand, with 3Q revenue of $96.3M up 23% year over year and management expanding reimbursement support, pharmacy-network utilization, and the sales force to convert more prescriptions into filled scripts without relying on a broad pricing reset. Gross margins above 95% and a 3Q GAAP net loss of just $0.7M suggest meaningful operating leverage, while FY26 OpEx is guided below $500M and the company remains on track for improved profitability as revenue scales. The outlook is further strengthened by ACCEL enrolling ahead of schedule with Phase 3 data expected in 2H27, the potential for CIC to roughly double IBSRELA’s addressable market, and added patent protection extending the tenapanor franchise into 2041.
Bears say
Ardelyx is vulnerable to regulatory uncertainty because it may rely on accelerated approval strategies, yet regulators can still demand additional data or longer studies that delay commercialization and raise development costs. Its ability to gain traction also depends on securing product labels with favorable features, and any weaker-than-expected labeling could materially limit physician adoption and market penetration for IBSRELA and XPHOZAH. In addition, changes in reimbursement pricing structures could pressure realized sales and margins, making the company’s commercial execution more fragile even after approval.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Ardelyx (ARDX) Forecast
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares